{"entity":{"id":"nct06329947","kind":"trial","name":"A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by Rui-hua Xu, MD, PhD, not yet recruiting.","summary":"A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD is a phase 2, interventional study registered as NCT06329947 by Rui-hua Xu, MD, PhD, with a registry enrolment figure of 37 participants, started 2024-05-22 and due to reach its primary completion in 2025-01-01. Interventions recorded: Surufatinib 250mg/d qd once daily. Conditions listed: Advanced Pancreatic Cancer. Primary outcome: objective response rate (ORR). Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed metastatic pancreatic cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06329947","url":"https://clinicaltrials.gov/study/NCT06329947"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06329947","phase":"2","setting":"A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD","sponsor":"Rui-hua Xu, MD, PhD","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06329947/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}